Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

5 意见
administrator
administrator
08/09/23

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个